News

Under the alliance, Cellular Genomics (CGI) has been applying its proprietary chemical genetics analog sensitive kinase (ASKA) technology to a number of target kinases selected by Serono. The

Seattle Genetics entered into the antibody-drug conjugate (ADC) collaboration with CuraGen in June 2004, at which time CuraGen paid an upfront fee of $2 million for access to

This is the first study to evaluate the company’s oral lead product candidate, talabostat (PT-100), as a single agent in patients with advanced metastatic melanoma. The trial is

The independent drug safety oversight board will oversee the management of important safety issues such as recommending information and updates for placement on the Drug Watch, resolving disagreements

Under the terms of the agreement, Avalon will hold exclusive rights to develop and commercialize VX-944 worldwide for the treatment of various cancers. Avalon will make up to

The grant award will be used to fund SIGA and TransTech Pharma’s joint research efforts directed toward the discovery, optimization, and advancement of lead drug candidates for smallpox

Insegia is an investigational therapeutic immunotherapy directed at the growth hormone gastrin. This study randomized 383 previously untreated patients with metastatic pancreatic cancer, to receive Insegia plus gemcitabine

4SC will apply its integrated drug discovery platform to develop drug candidates, ready to enter clinical trials, against two specific targets provided by Sanwa Kagaku Kenkyusho (SKK). 4SC

Vanos, which is manufactured by Patheon Inc in Canada, is a patented corticosteroid cream formulation for once or twice daily application which embodies the heritage of Lidex (fluocinonide),